ライフサイエンスコーパス: CpG oligodeoxynucleotide

1 following stimulation with bacterial DNA or CpG oligodeoxynucleotide.

2 pffer cells produced IL-1beta in response to CpG oligodeoxynucleotide.

3 -labile enterotoxin designated LT(R192G), or CpG oligodeoxynucleotide.

4 , LPS, pertussis toxin (PTX), flagellin, and CpG oligodeoxynucleotide.

5 th the pathogen-associated molecular pattern CpG oligodeoxynucleotides.

6 e level of the endosome, as is the case with CpG oligodeoxynucleotides.

7 C or a specific Toll-like receptor 9 ligand, CpG oligodeoxynucleotides.

8 (B6) controls were treated with either AC or CpG-oligodeoxynucleotides.

9 , or HCV-LP and the combination of AS01B and CpG oligodeoxynucleotides 10105.

10 cle also accommodated the co-localization of CpG oligodeoxynucleotide 1826, a single-stranded synthet

11 The biological activity of CpG oligodeoxynucleotide 2216 (ODN2216), a Toll-like rec

12 We have established that CpG oligodeoxynucleotide 5mers, of sequence type CGNNN (

13 implicated in the action of or resistance to CpG oligodeoxynucleotide 5mers.

14 We show that stimulation with a CpG oligodeoxynucleotide, a Toll-like receptor 9 agonist

15 In vivo, CpG-oligodeoxynucleotide, a TLR9 agonist, given i.p. to

16 The potential of CpG oligodeoxynucleotide-activated PDC to induce prolife

17 es in Qa-1(b)-deficient mice, or transfer of CpG-oligodeoxynucleotide-activated Qa-1(b)-deficient DC

18 Triggering of TLR 9 with CpG oligodeoxynucleotides activates PDCs to up-regulate

19 nt of the fusion (F) protein (DS-Cav1) and a CpG oligodeoxynucleotide adjuvant encapsulated within po

20 Thus, a previously unrecognized benefit of CpG oligodeoxynucleotides adjuvants is their ability to

21 Injection of R-848 and CpG oligodeoxynucleotides alone enhanced the innate immu

22 We evaluated the effects of CpG oligodeoxynucleotides alone or in combination with g

23 sential role in DC responses to unmethylated CpG oligodeoxynucleotide: although responses to lipopoly

24 ntially stimulated IL-17 production, whereas CpG oligodeoxynucleotide and polyinosinic:polycytidylic

25 in the case in neovascularization induced by CpG oligodeoxynucleotides and herpes simplex virus infec

26 oduction can be induced both by unmethylated CpG-oligodeoxynucleotide and by double-stranded RNA.

27 ing phenotype reversal than the TLR agonists CpG-oligodeoxynucleotide and Gardiquimod.

28 atory signals, such as IFN-gamma, IFN-alpha, CpG oligodeoxynucleotides, and 4-1BB ligation.

29 hages in response to Corynebacterium parvum, CpG oligodeoxynucleotides, anti-CD40 and low molecular w

30 IgG2b Abs was seen when rPA was given with a CpG oligodeoxynucleotide as adjuvant, suggesting a role

31 utilize dendritic cells in combination with CpG oligodeoxynucleotides as a vaccine delivery vector t

32 4 ligand LPS or the TLR9 ligand unmethylated CpG oligodeoxynucleotide before transient brain ischemia

33 xpansion mixture containing IL-21, anti-BCR, CpG oligodeoxynucleotide, CD40L, and IL-2, we were able

34 Moreover, binding of HMGB1 to class A CpG oligodeoxynucleotides considerably augmented cytokin

35 CpG oligodeoxynucleotide (CpG ODN) cellular uptake into

36 dritic cell efficiency, an immunostimulatory CpG oligodeoxynucleotide (CpG ODN) was combined with Ad5

37 ared with the well-established TLR-9 agonist CpG oligodeoxynucleotide (CpG), and study the participat

38 cines included incomplete Freund's adjuvant, CpG oligodeoxynucleotide (CpG), and the HLA-A2-restricte

39 express TLR9 intracellularly and respond to CpG oligodeoxynucleotide (CpG-ODN) by producing IFN-gamm

40 This study examined the effect of CpG oligodeoxynucleotide (CpG-ODN), the TLR9 ligand, on

41 ith the dsRNA synthetic analog poly(I:C) and CpG oligodeoxynucleotides (CpG DNA), respective ligands

42 se induced by inclusion of immunostimulatory CpG oligodeoxynucleotides (CpG DNA).

43 f a plasmid-expressing Flt3 ligand (pFL) and CpG oligodeoxynucleotides (CpG ODN) as a combined nasal

44 Thus, we assessed the effects of CpG oligodeoxynucleotides (CpG ODN) on Langerhans cell (

45 otein and a TLR7/8 agonist or a TLR9 ligand [CpG oligodeoxynucleotides (CpG ODN)] had significantly i

46 mbination delivery of anti-PD-1 antibody and CpG oligodeoxynucleotides (CpG ODNs) has been demonstrat

47 ith T-helper 1 (Th-1)-like immunostimulatory CpG oligodeoxynucleotides (CpG ODNs) would improve thera

48 ating B-CLL cells with TLR9 agonists, type B CpG oligodeoxynucleotides (CpG-B ODNs), induces signific

49 CpG oligodeoxynucleotides (CpG-ODN) administered during

50 ar chaperone, is highly efficient in binding CpG oligodeoxynucleotides (CpG-ODN), the microbial DNA m

51 CpG oligodeoxynucleotides (CpG-ODNs) affect innate and a

52 CpG-DNA and its related synthetic CpG oligodeoxynucleotides (CpG-ODNs) play an important r

53 CpG oligodeoxynucleotides (CpG-ODNs) stimulate innate an

54 CpG-oligodeoxynucleotide (CpG ODN)-based Toll-like recep

55 40L), LPS, and, to a lesser extent, IL-4 and CpG-oligodeoxynucleotide (CpG), induced significant expr

56 o Toll-like receptor 9 (TLR9) stimulation by CpG-oligodeoxynucleotide (CpG-ODN) was integrated into m

57 CpG-oligodeoxynucleotides (CpG-ODNs) are potent immune s

58 GNP causes specific inhibition of TLR9 (CpG oligodeoxynucleotides; CpG-ODNs) signal in macrophag

59 Furthermore, vaccination with CpG-oligodeoxynucleotide decreases the number of T(reg)

60 ing stimuli, as the T(H)1-inducing adjuvant, CpG oligodeoxynucleotide, did not promote either c-Kit o

61 ious nonself context in a tumor-by injecting CpG-oligodeoxynucleotides directly into the tumor-would

62 e have shown that mycobacterial antigens and CpG oligodeoxynucleotides downmodulate airway allergic i

63 Coadministration of CpG oligodeoxynucleotides during sensitization of TLR4-m

64 In addition, the TLR ligands LPS and CpG oligodeoxynucleotide enhanced the level of FcRn expr

65 s against IL-6 to B cell cultures along with CpG oligodeoxynucleotides essentially abolished the CpG

66 combination of BNP-CPT and immunostimulating CpG oligodeoxynucleotides exhibited enhanced survival re

67 CLL cells by using anti-IgM, imiquimod, and CpG oligodeoxynucleotide for BCR, TLR7, and TLR9, respec

68 After culturing PDC with VIP and CpG oligodeoxynucleotides for 48 h, expression of surfac

69 8, which signals only via TLR7 in mice, with CpG oligodeoxynucleotides for their capacity to induce H

70 ccharide (LPS) and cytosine-phospho-guanine (CpG) oligodeoxynucleotides for 48 h.

71 the TLR9 agonist cytosine-phosphate-guanine (CpG) oligodeoxynucleotide formulated in a squalene-based

72 Although the efficacy of CpG oligodeoxynucleotides has been thought to depend on

73 CpG oligodeoxynucleotides have been investigated in airw

74 Because synthetic RNA analogues and CpG oligodeoxynucleotides have been safely used in clini

75 Stimulation with anti-micro, LPS, CpG oligodeoxynucleotide, HSV-1, or CTLA-4 Ig activates

76 of an iodine-131 ((131)I) radionuclide and a CpG oligodeoxynucleotide immunostimulant, driven by the

77 This proliferation is blocked by inhibitory CpG oligodeoxynucleotides, implicating the TLR9 (or poss

78 When coinjected with a CpG oligodeoxynucleotide in vivo, IRS were shown to inhi

79 tivation of the innate immune response using CpG oligodeoxynucleotides in combination with anti-TNF-a

80 f an agonistic anti-CD40 mAb (anti-CD40) and CpG-oligodeoxynucleotides in activating macrophages to i

81 Activation of DC using CpG-oligodeoxynucleotides in Qa-1(b)-deficient mice, or

82 Adjuvants AS01, MF59, AS03, and CpG-oligodeoxynucleotide, included in licensed vaccines,

83 Thus, a major mechanism by which CpG oligodeoxynucleotide increase cross presentation by

84 IL-1beta but not CpG-oligodeoxynucleotides, increased lipid accumulation

85 Recent studies have shown CpG oligodeoxynucleotide induce tumor necrosis factor-re

86 VEGF expression in vitro and also decreased CpG oligodeoxynucleotide induced VEGF-dependent neovascu

87 w that treatment with anti-CD3/CD28 Abs plus CpG oligodeoxynucleotides induces robust expression of I

88 lation of innate immune responses, including CpG oligodeoxynucleotides introduced into the BAX 335 co

89 The data show that intratumor injection of CpG-oligodeoxynucleotides is a promising strategy for re

90 Upon stimulation with CpG oligodeoxynucleotides, ligands for Toll-like recepto

91 Immunization with CpG oligodeoxynucleotide-modified nanoparticles resulted

92 either Quil A or with Montanide ISA 720 plus CpG oligodeoxynucleotide (ODN) and was observed in both

93 this study, we evaluated the use of topical CpG oligodeoxynucleotide (ODN) as adjuvant to generate s

94 Treatment of RAW264.7 cells with CpG oligodeoxynucleotide (ODN) for both 18 and 42 h resu

95 conjugate formulated with adjuvants alum and CpG oligodeoxynucleotide (ODN) generated heroin "immunoa

96 The strong Th1 response triggered by CpG oligodeoxynucleotide (ODN) inhibits the development

97 The addition of either CpG oligodeoxynucleotide (ODN) or anti-B-cell-receptor a

98 reports of apoptosis after B-CLL exposure to CpG oligodeoxynucleotide (ODN) raised questions about a

99 ing a NF-kB-specific decoy DNA tethered to a CpG oligodeoxynucleotide (ODN) targeting Toll-like recep

100 mune response by artificial stimulation with CpG oligodeoxynucleotide (ODN), a TLR9 agonist, would re

101 o secrete IFN-alpha when stimulated with the CpG oligodeoxynucleotide (ODN)-2216.

102 In the present study, we developed a CpG oligodeoxynucleotide (ODN)-based immune intervention

103 rk examines the ability of immunostimulatory CpG oligodeoxynucleotides (ODN) adsorbed onto cationic p

104 CpG oligodeoxynucleotides (ODN) and GM-CSF are potent va

105 s from immunized mice to TLR9 and 4 agonists CpG oligodeoxynucleotides (ODN) and LPS.

106 s studies established that immunostimulatory CpG oligodeoxynucleotides (ODN) can increased the resist

107 Vaccination with leishmanial Ag and CpG oligodeoxynucleotides (ODN) confers sustained cellul

108 CpG oligodeoxynucleotides (ODN) have potent effects on i

109 CpG oligodeoxynucleotides (ODN) have potent immunostimul

110 Immunostimulatory CpG oligodeoxynucleotides (ODN) have proven effective as

111 Immunostimulatory CpG oligodeoxynucleotides (ODN) improve host resistance

112 The direct response of NK cells to CpG oligodeoxynucleotides (ODN) in the presence of FcR s

113 s studies established that immunostimulatory CpG oligodeoxynucleotides (ODN) increase the resistance

114 We evaluated the immunomodulatory effect of CpG oligodeoxynucleotides (ODN) on the immunogenicity of

115 CpG oligodeoxynucleotides (ODN) show promise as immunopr

116 We tested the potential of CpG oligodeoxynucleotides (ODN) to reverse the increased

117 granuloma model, we examined the ability of CpG oligodeoxynucleotides (ODN) to suppress Th2-type cyt

118 CpG oligodeoxynucleotides (ODN) were identified that sti

119 after intranasal coimmunization with RANTES, CpG oligodeoxynucleotides (ODN), or CT.

120 intravaginally with either the TLR9 agonist, CpG oligodeoxynucleotides (ODN), or the TLR7 agonist, im

121 We examined the ability of unmethylated CpG oligodeoxynucleotides (ODN), which are potent induce

122 ands, including keratin, and some classes of CpG oligodeoxynucleotides (ODN).

123 These effects are mimicked by synthetic CpG oligodeoxynucleotides (ODN).

124 munomodulatory cytosine-phosphate-guanidine (CpG) oligodeoxynucleotide (ODN), a toll-like receptor 9

125 Several types of CpG-oligodeoxynucleotides (ODN) have been recently chara

126 ere cultured with or without a TLR9 agonist (CpG oligodeoxynucleotide [ODN] 2006) for 2 d and then as

127 Bacterial DNA and immunostimulatory CpG oligodeoxynucleotides (ODNs) activate the innate imm

128 Although vaginal application of CpG oligodeoxynucleotides (ODNs) and poly I:C has been s

129 CpG oligodeoxynucleotides (ODNs) are synthetic DNA seque

130 nking the CpG motif and on the DNA backbone, CpG oligodeoxynucleotides (ODNs) can induce relatively m

131 CpG oligodeoxynucleotides (ODNs) may prevent mortality f

132 harnessing innate immunity via TLR9 agonist CpG oligodeoxynucleotides (ODNs) modulates age-related d

133 Application of CpG oligodeoxynucleotides (ODNs) resulted in neutrophil

134 CpG oligodeoxynucleotides (ODNs) signal through TLR9 to

135 Immune-enhancing CpG and non-CPG oligodeoxynucleotides (ODNs) stimulate Ag presentati

136 CpG oligodeoxynucleotides (ODNs), which mimic bacterial

137 Unmethylated CpG-oligodeoxynucleotides (ODNs) are generally thought o

138 our results show that prior stimulation with CpG oligodeoxynucleotide or Escherichia coli DNA prevent

139 er TLR7/9 activation with different types of CpG oligodeoxynucleotides or tick-borne encephalitis vac

140 t human plasmacytoid DC, activated by either CpG oligodeoxynucleotides or viral infection, also respo

141 il), and increased after treatment with LPS, CpG oligodeoxynucleotides, or a gram-positive bacterium

142 viously shown that intratumoral injection of CpG oligodeoxynucleotide plus systemic chemotherapy can

143 Coinjection of CpG oligodeoxynucleotides, potent inducers of inflammati

144 rolphosphate and tetanus toxoid in alum plus CpG-oligodeoxynucleotides produced high secondary titers

145 ion of these cells, 2) activation of FC with CpG-oligodeoxynucleotide promotes CD4(+)25(-) T cell dif

146 nstrate that IL-12, IL-18, and TLR 9 agonist CpG oligodeoxynucleotides reduce the level of fusion-med

147 emulsion or aluminum hydroxide combined with CpG oligodeoxynucleotides resulted in high levels of ant

148 Upon detection, CpG oligodeoxynucleotides signal the immune system to ge

149 administration of the TLR9 agonist molecule CpG oligodeoxynucleotide stimulated protective immunity

150 phocytes secrete IFN-gamma upon culture with CpG oligodeoxynucleotide-stimulated dendritic cells (DCs

151 idazoquinolines (imiquimod and R-848) and to CpG oligodeoxynucleotides stimulation, resulting in enha

152 s, we investigated the effect of exposure to CpG oligodeoxynucleotides (TLR9 ligands) prior to neonat

153 ated antigens and delivers immunostimulatory CpG oligodeoxynucleotides to DCs.

154 We investigated the ability of CpG-oligodeoxynucleotide to generate an anti-tumor CD8+

155 s a cofactor for TLR9 activation, delivering CpG-oligodeoxynucleotides to TLR9 in endolysosomes.

156 g copper-free click chemistry, we conjugated CpG oligodeoxynucleotide toll-like receptor 9 (TLR9) ago

157 d by chloroquine, whereas TLR9 activation by CpG oligodeoxynucleotides was abolished.

158 Intratumor injection of CpG-oligodeoxynucleotides was shown to induce a tumor-sp

159 that BCG's antitumor properties are akin to CpG oligodeoxynucleotide, where the cytokine response to

160 ophosphoryl lipid A and cholesterol-modified CpG oligodeoxynucleotides, which can bind His-tagged pro

161 7 and TLR 8, and cytosine-phosphate-guanine (CpG) oligodeoxynucleotides, which activate TLR 9-express